Xlife Sciences (VTX:XLS) Full Year 2022 Results
Key Financial Results
-
Net income: CHF14.3m (down 73% from FY 2021).
-
EPS: CHF2.72 (down from CHF11.30 in FY 2021).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Xlife Sciences Revenues and Earnings Beat Expectations
Revenue exceeded analyst estimates by 28%. Earnings per share (EPS) also surpassed analyst estimates.
Looking ahead, revenue is expected to decline by 13% p.a. on average during the next 2 years, while revenues in the Life Sciences industry in Switzerland are expected to grow by 11%.
Performance of the Swiss Life Sciences industry.
The company's shares are up 5.8% from a week ago.
Risk Analysis
It's necessary to consider the ever-present spectre of investment risk. We've identified 5 warning signs with Xlife Sciences (at least 1 which is concerning), and understanding them should be part of your investment process.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here